Literature DB >> 25728920

Expanding the Mutation Spectrum Affecting αIIbβ3 Integrin in Glanzmann Thrombasthenia: Screening of the ITGA2B and ITGB3 Genes in a Large International Cohort.

Alan T Nurden1, Xavier Pillois, Mathieu Fiore, Marie-Christine Alessi, Mariana Bonduel, Marie Dreyfus, Jenny Goudemand, Yves Gruel, Schéhérazade Benabdallah-Guerida, Véronique Latger-Cannard, Claude Négrier, Diane Nugent, Roseline D Oiron, Margaret L Rand, Pierre Sié, Marc Trossaert, Lorenzo Alberio, Nathalie Martins, Peggy Sirvain-Trukniewicz, Arnaud Couloux, Mathias Canault, Juan Pablo Fronthroth, Mathilde Fretigny, Paquita Nurden, Roland Heilig, Christine Vinciguerra.   

Abstract

We report the largest international study on Glanzmann thrombasthenia (GT), an inherited bleeding disorder where defects of the ITGA2B and ITGB3 genes cause quantitative or qualitative defects of the αIIbβ3 integrin, a key mediator of platelet aggregation. Sequencing of the coding regions and splice sites of both genes in members of 76 affected families identified 78 genetic variants (55 novel) suspected to cause GT. Four large deletions or duplications were found by quantitative real-time PCR. Families with mutations in either gene were indistinguishable in terms of bleeding severity that varied even among siblings. Families were grouped into type I and the rarer type II or variant forms with residual αIIbβ3 expression. Variant forms helped identify genes encoding proteins mediating integrin activation. Splicing defects and stop codons were common for both ITGA2B and ITGB3 and essentially led to a reduced or absent αIIbβ3 expression; included was a heterozygous c.1440-13_c.1440-1del in intron 14 of ITGA2B causing exon skipping in seven unrelated families. Molecular modeling revealed how many missense mutations induced subtle changes in αIIb and β3 domain structure across both subunits, thereby interfering with integrin maturation and/or function. Our study extends knowledge of GT and the pathophysiology of an integrin.
© 2015 WILEY PERIODICALS, INC.

Entities:  

Keywords:  Glanzmann thrombasthenia; ITGA2B; ITGB3; integrin αIIbβ3; molecular modeling

Mesh:

Substances:

Year:  2015        PMID: 25728920     DOI: 10.1002/humu.22776

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  24 in total

1.  An intracytoplasmic β3 Leu718 deletion in a patient with a novel platelet phenotype.

Authors:  Paquita Nurden; Jean-Claude Bordet; Xavier Pillois; Alan T Nurden
Journal:  Blood Adv       Date:  2017-03-10

Review 2.  Genomic landscape of megakaryopoiesis and platelet function defects.

Authors:  Elisa Bianchi; Ruggiero Norfo; Valentina Pennucci; Roberta Zini; Rossella Manfredini
Journal:  Blood       Date:  2016-01-19       Impact factor: 22.113

3.  Clinical and molecular insights into Glanzmann's thrombasthenia in China.

Authors:  L Zhou; M Jiang; H Shen; T You; Z Ding; Q Cui; Z Ma; F Yang; Z Xie; H Shi; J Su; L Cao; J Lin; J Yin; L Dai; H Wang; Z Wang; Z Yu; C Ruan; L Xia
Journal:  Clin Genet       Date:  2018-05-22       Impact factor: 4.438

4.  Naturally occurring point mutation Cys460Trp located in the I-EGF1 domain of integrin β3 alters the binding of some anti-HPA-1a antibodies.

Authors:  Sarah Theresa Holzwarth; Behnaz Bayat; Jieqing Zhu; Roongaroon Phuangtham; Lars Fischer; Doris Boeckelmann; Lida Röder; Heike Berghöfer; Silke Schmidt; Gregor Bein; Sentot Santoso
Journal:  Transfusion       Date:  2020-08-08       Impact factor: 3.157

Review 5.  Inherited Platelet Disorders: An Updated Overview.

Authors:  Verónica Palma-Barqueros; Nuria Revilla; Ana Sánchez; Ana Zamora Cánovas; Agustín Rodriguez-Alén; Ana Marín-Quílez; José Ramón González-Porras; Vicente Vicente; María Luisa Lozano; José María Bastida; José Rivera
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

6.  Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding.

Authors:  Sarah K Westbury; Matthias Canault; Daniel Greene; Emilse Bermejo; Katharine Hanlon; Michele P Lambert; Carolyn M Millar; Paquita Nurden; Samya G Obaji; Shoshana Revel-Vilk; Chris Van Geet; Kate Downes; Sofia Papadia; Salih Tuna; Christopher Watt; Kathleen Freson; Michael A Laffan; Willem H Ouwehand; Marie-Christine Alessi; Ernest Turro; Andrew D Mumford
Journal:  Blood       Date:  2017-06-21       Impact factor: 22.113

7.  Novel mutations in RASGRP2, which encodes CalDAG-GEFI, abrogate Rap1 activation, causing platelet dysfunction.

Authors:  María Luisa Lozano; Aaron Cook; José María Bastida; David S Paul; Gemma Iruin; Ana Rosa Cid; Rosa Adan-Pedroso; José Ramón González-Porras; Jesús María Hernández-Rivas; Sarah J Fletcher; Ben Johnson; Neil Morgan; Francisca Ferrer-Marin; Vicente Vicente; John Sondek; Steve P Watson; Wolfgang Bergmeier; José Rivera
Journal:  Blood       Date:  2016-05-27       Impact factor: 22.113

Review 8.  Glanzmann Thrombasthenia: Perspectives from Clinical Practice on Accurate Diagnosis and Optimal Treatment Strategies.

Authors:  Natalie Mathews; Georges-Etienne Rivard; Arnaud Bonnefoy
Journal:  J Blood Med       Date:  2021-06-11

Review 9.  Profiling the Genetic and Molecular Characteristics of Glanzmann Thrombasthenia: Can It Guide Current and Future Therapies?

Authors:  Alan Nurden
Journal:  J Blood Med       Date:  2021-07-08

10.  Introducing high-throughput sequencing into mainstream genetic diagnosis practice in inherited platelet disorders.

Authors:  José M Bastida; María L Lozano; Rocío Benito; Kamila Janusz; Verónica Palma-Barqueros; Mónica Del Rey; Jesús M Hernández-Sánchez; Susana Riesco; Nuria Bermejo; Hermenegildo González-García; Agustín Rodriguez-Alén; Carlos Aguilar; Teresa Sevivas; María F López-Fernández; Anna E Marneth; Bert A van der Reijden; Neil V Morgan; Steve P Watson; Vicente Vicente; Jesús M Hernández-Rivas; José Rivera; José R González-Porras
Journal:  Haematologica       Date:  2017-10-05       Impact factor: 9.941

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.